Fig. 2

MiR-3935 was targeted by LINC00992. a LncLocator predicted LINC00992 subcellular location. b FISH analysis of LINC00992 distribution in prostate cancer cells. Scale bar = 30 μm. c RNA isolation of nuclear and cytoplasmic fractions assayed the subcellular distribution of LIN00992 in prostate cancer cells. d Top three miRNAs which might interact with LINC00992 were predicted by DIANA-lncBase. e After transfection of LINC00992-silencing plasmids, the expression of miR-3157-5p, miR-1178-3p and miR-3935 was examined via qRT-PCR. f Following LINC00992 upregulation, qRT-PCR tested the levels of miR-3157-5p, miR-1178-3p and miR-3935 in DU145 and PC3 cells. g RNA pull down assay was implemented to testify the binding capacity between LINC00992 and miR-3935. h miR-3935 overexpression efficiency and inhibition efficiency were examined by qRT-PCR. i RIP assay disclosed the binding of miR-3935 to LINC00992 in the anti-Ago2 group. j The potential binding site between LINC00992 and miR-3935 was shown. And the luciferase activity of LINC00992-WT or LINC00992-MUT reporter was assessed via luciferase reporter assay in DU145 and PC3 cells after transfection with miR-3935-mimics, miR-3935-inhibitor, NC-inhibitor or NC-mimics. *P < 0.05, **p < 0.01, ***p < 0.001